Opposition proceeding

Forward Pharma Announces the Decision of the Enlarged Board of Appeal of the European Patent Office in the EP2801355 Petition for Review

Retrieved on: 
Tuesday, December 6, 2022
Sclerosis, Opposition proceeding, Forward, Petition, DMF, Settlement, Opposition, Music, Fine chemical, Biogen

The EBA’s rejection of the Petition ends the Opposition Proceeding in favor of the opponents and represents an unsuccessful outcome of the Opposition Proceeding, resulting in no royalties being due to the Company from Biogen based on Biogen’s future net sales of Tecfidera® or other DMF products for multiple sclerosis outside the United States, as defined in the Settlement and License Agreement by and among Forward, subsidiaries of Biogen Inc. and certain other parties thereto.

Key Points: 
  • The EBA’s rejection of the Petition ends the Opposition Proceeding in favor of the opponents and represents an unsuccessful outcome of the Opposition Proceeding, resulting in no royalties being due to the Company from Biogen based on Biogen’s future net sales of Tecfidera® or other DMF products for multiple sclerosis outside the United States, as defined in the Settlement and License Agreement by and among Forward, subsidiaries of Biogen Inc. and certain other parties thereto.
  • As previously disclosed, because the Company was also unsuccessful in the U.S.
  • Interference Proceeding after all appeals, the Company will not be entitled to future royalties from the United States.
  • Forward Pharma A/S Investor Relations Contact:

Forward Pharma Reports Financial and Operating Results for the Year Ended December 31, 2021

Retrieved on: 
Friday, April 8, 2022
Hearing, FWP, Company, Mission statement, NASDAQ, Group, Risk, Opposition proceeding, Coronavirus, EPO, Petition, Research, TBA, EBA, European Patent Convention, Element, Review, Patent, U.S. Securities and Exchange Commission, Danish krone, Opposition, Year, GLOBE, Liu v. Securities and Exchange Commission, Annual report, Insurance, Online gambling, Animal, Biogen

COPENHAGEN, Denmark, April 08, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (we, Forward or the Company and, together with its subsidiaries, the Group), today reported consolidated financial results for the year ended December 31, 2021.

Key Points: 
  • COPENHAGEN, Denmark, April 08, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (we, Forward or the Company and, together with its subsidiaries, the Group), today reported consolidated financial results for the year ended December 31, 2021.
  • Operating Results for the Years Ended December 31, 2021 and 2020
    Our research and development costs for the years ended December31, 2021 and 2020 were $226,000 and $327,000, respectively.
  • Our general and administrative costs for the years ended December31, 2021 and 2020 were $3.6million and $3.1million, respectively.
  • Financial Position as of December 31, 2021
    At December 31, 2021, the Group had cash and cash equivalents of $70.8 million and working capital of $70.8 million.

Forward Pharma Announces the Decision of the Technical Board of Appeal of the European Patent Office in the EP2801355 Appeal Hearing

Retrieved on: 
Monday, September 6, 2021
Intellectual property law, European Patent Organisation, Law, Government, Opposition procedure before the European Patent Office, Appeal procedure before the European Patent Office, European Patent Office, European Patent Convention, Opposition proceeding

COPENHAGEN, Denmark, Sept. 06, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (we, Forward or the Company), today announced that the Technical Board of Appeal (the TBA) of the European Patent Office (the EPO) has dismissed Forwards appeal of the previous decision of the EPO Opposition Division to revoke the EP2801355 patent (the 355 patent) following the oral hearing.

Key Points: 
  • COPENHAGEN, Denmark, Sept. 06, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (we, Forward or the Company), today announced that the Technical Board of Appeal (the TBA) of the European Patent Office (the EPO) has dismissed Forwards appeal of the previous decision of the EPO Opposition Division to revoke the EP2801355 patent (the 355 patent) following the oral hearing.
  • The TBA made its decision after considering Forwards appeal against the decision of the Opposition Division and third-party submissions from several opponents.
  • The TBA will issue detailed reasons for the decision in written form in due course, and following receipt and review of these, Forward will announce future plans for the Company.
  • The denial of a petition for review would end the Opposition Proceeding in favor of the opponents.

Forward Pharma Announces Rescheduling of the EP2801355 Appeal Hearing to September 6, 2021 due to COVID-19 Restrictions

Retrieved on: 
Tuesday, January 12, 2021
Intellectual property law, European Patent Organisation, Canadian Intellectual Property Office, Canadian intellectual property law, Canadian trademark law, Trademarks Opposition Board, Opposition procedure before the European Patent Office, Opposition proceeding

The new hearing date is set for September 6, 2021.

Key Points: 
  • The new hearing date is set for September 6, 2021.
  • On January 29, 2018, the Opposition Division of the EPO concluded the oral proceedings concerning the 355 Patent (the Opposition Proceeding).
  • Management expects the TBA to issue a ruling on the same day as the hearing, with a fully reasoned decision approximately two months following the hearing.
  • The denial of a request to rehear would end the Opposition Proceeding in favor of the opponents.

Bound2B Files Patent Infringement Case Against the Ardagh Group, Xolution and Weider in Germany

Retrieved on: 
Tuesday, June 2, 2020
Law by country, Intellectual property law, Politics by country, European Patent Organisation, European Patent Office, European Patent Convention, Opposition proceeding, Patent

Bound2B - owner of EP' 930, covering devices for closing beverage and corresponding food containers, in particular resealable cans believes that resealable cans equipped with Xolution's XO System infringe its patent EP' 930.

Key Points: 
  • Bound2B - owner of EP' 930, covering devices for closing beverage and corresponding food containers, in particular resealable cans believes that resealable cans equipped with Xolution's XO System infringe its patent EP' 930.
  • Such cans have been distributed by Weider in Germany.
  • The validity of EP' 930 was confirmed in opposition proceedings before the European Patent Office (EPO) in 2011.
  • This filing follows legal proceedings filed in 2018 by Bound2B against a further company of the Ardagh Group in the Netherlands with regard to an alleged breach of contract by Ardagh.

Cantargia Reports Filing of Opposition Against Cantargia Patent in Europe

Retrieved on: 
Thursday, October 10, 2019
Intellectual property law, Law by country, Patent law, European Patent Organisation, Opposition proceeding, Patent, Opposition procedure before the European Patent Office, Outline of patents

The current opponent, Mab Discovery GmbH, also filed an opposition against the mother patent in 2016.

Key Points: 
  • The current opponent, Mab Discovery GmbH, also filed an opposition against the mother patent in 2016.
  • That opposition was unsuccessful and the mother patent, valid until 2032, remains in force after the opposition proceedings were concluded in 2018.
  • These patent families concerning IL1RAP comprise more than 80 granted patents and almost 30 additional pending patent applications worldwide.
  • Mab Discovery has now filed an opposition against that patent, and the next step is a formal procedure where Cantargia is invited to comment on the opposition.

Tonix Pharmaceuticals Announces that the European Patent Office Opposition Division Has Upheld Its Patent for the Use of the Active Ingredient in TNX-102 SL, Cyclobenzaprine, for the Treatment of PTSD

Retrieved on: 
Monday, October 7, 2019
Psychiatry, Patent law, European Patent Organisation, Military, Articles, Opposition proceeding, Trademark law, Posttraumatic stress disorder, Tonix Pharmaceuticals

This patent was originally granted by the EPO in September 2017 and an opposition was filed against the patent in June 2018.

Key Points: 
  • This patent was originally granted by the EPO in September 2017 and an opposition was filed against the patent in June 2018.
  • In addition to these patents, Tonix owns patents covering TNX-102 SL and its use to treat PTSD in the U.S., Europe, and other countries.
  • said, We believe that the outcome of the European opposition proceedings adds strength to the overall patent estate for TNX-102 SL.
  • Tonixs lead program is for the development of Tonmya* (TNX-102 SL), which is in Phase 3 development as a bedtime treatment for PTSD.

The European Patent Office (EPO) Disapproves British Court and New U.S. Patent Granted for Regen Lab on Autologous Biological Glue

Retrieved on: 
Friday, March 1, 2019
Intellectual property law, Law, Countries, European Patent Organisation, Patent law, Patent offices, European Patent Office, Patent, European Patent Convention, Opposition proceeding

LE MONT-SUR-LAUSANNE, Switzerland, March 1, 2019 /PRNewswire/ -- In Europe, the Regen Lab group ("Regen") defends one of its patents (EP2073862B, method of PRP preparation) in opposition proceedings before the European Patent Office (EPO), where alleged patent infringers have contested its validity.

Key Points: 
  • LE MONT-SUR-LAUSANNE, Switzerland, March 1, 2019 /PRNewswire/ -- In Europe, the Regen Lab group ("Regen") defends one of its patents (EP2073862B, method of PRP preparation) in opposition proceedings before the European Patent Office (EPO), where alleged patent infringers have contested its validity.
  • The EPO expressed the view that enforcing a granted patent constitutes a lawful exercise of a patentee's right until such patent has been declared invalid.
  • Regen is also delighted to announce that the United States Patent and Trademark Office (USPTO) has granted to Regen U.S. Patent No.
  • 10,226,516covering its Autologous Biological Glue entitled "Process, Tube And Device For The Preparation Of Wound Healant Composition".